Go Pro
NASDAQ:BTTX

Better Therapeutics (BTTX) Stock Price, News & Analysis

Better Therapeutics logo

About Better Therapeutics Stock (NASDAQ:BTTX)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
8,000 shs
Market Capitalization
$4 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Better Therapeutics, Inc. is a clinical-stage digital therapeutics company focused on developing prescription software-based treatments for cardiometabolic diseases. Its lead product candidate, BT-001, is a behavior-change program delivered via a smartphone application, designed to address underlying drivers of type 2 diabetes and hypertension through cognitive behavioral therapy techniques. The company’s platform is built to engage patients in personalized lifestyle modification, leveraging real-time feedback and data analytics to support sustained clinical improvements.

BT-001 is being evaluated in pivotal clinical trials under FDA investigational device exemptions, with studies examining its impact on glycemic control and blood pressure reduction. Better Therapeutics collaborates with academic research centers and healthcare providers to validate its therapeutic approach, aiming to secure FDA clearance as a prescription digital therapeutic. The company’s evidence-generation strategy includes randomized controlled trials and real-world evidence initiatives to demonstrate safety, efficacy and long-term adherence benefits.

Founded in 2016 and headquartered in Redwood City, California, Better Therapeutics operates primarily in the United States, with plans to expand its commercial and regulatory footprint internationally. The company is led by CEO Sean Duffy, who brings extensive experience in digital health innovation, and a management team comprised of professionals in clinical development, regulatory affairs and commercial strategy. Better Therapeutics has assembled a scientific advisory board featuring thought leaders in endocrinology, behavioral science and digital health.

Better Therapeutics aims to transform chronic disease management by providing scalable, evidence-based digital interventions that complement traditional medical therapies. Its mission is to empower patients and healthcare systems with tools that address root causes of cardiometabolic conditions, improve clinical outcomes and reduce long-term healthcare costs.

AI Generated. May Contain Errors.

Receive BTTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Better Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BTTX Stock News Headlines

Better Therapeutics (BTTX) to Post Earnings on Thursday
BTTX Better Therapeutics, Inc. - Seeking Alpha
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
Janux Therapeutics Inc (JANX) Receives a Buy from BTIG
See More Headlines

BTTX Stock Analysis - Frequently Asked Questions

Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Better Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Cricut (CRCT), Zomedica (ZOM), Wells Fargo & Company (WFC) and Abbott Laboratories (ABT).

Company Calendar

Today
8/14/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Health services
Sub-Industry
Healthcare
Current Symbol
NASDAQ:BTTX
CIK
1832415
Fax
N/A
Employees
40
Year Founded
2015

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
40,580,000
Free Float
24,233,000
Market Cap
$4 thousand
Optionable
No Data
Beta
0.85

Social Links

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:BTTX) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners